March 2021 – PhD Candidate Shikha Nayar has published her work in Nature, A myeloid–stromal niche and gp130 rescue in NOD2-driven Crohn’s disease, demonstrating novel biological insights into NOD2-driven fibrosis in CD. Congratulations, Shikha!February 2021 – Congratulations to Kyle Gettler, Felix Chuang, and Rachel Levantovsky, who all had abstracts selected for lecture presentation at the Digestive Disease Week 2021 Meeting.
January 2021 – A protective variant in MRGPRX2, a receptor involved in mast cell activation, distinguishes inflamed regions in Ulcerative Colitis from non-inflamed regions, a finding by the Cho Lab described in a new study published in Gastroenterology.
Chen, E., Chuang, L. S., Giri, M., Villaverde, N., Hsu, N. Y., Sabic, K., … & Cho, J. H. (2021). Inflamed ulcerative colitis regions associated to MRGPRX2-mediated mast cell degranulation and cell activation modules, defining a new therapeutic target. Gastroenterology.
December 2020 – In a study published in Gastroenterology, we have shown that integration of genetic data from diverse populations improves prediction of IBD outcomes; the study of rare variants from diverse populations can highlight population specific risk variants for Ulcerative Colitis, such those in the very-early onset IBD associated gene LRBA. This study was featured by Nature Reviews Gastroenterology & Hepatology and by Mount Sinai.
Gettler, K., Levantovsky, R., Moscati, A., Giri, M., Wu, Y., Hsu, N. Y., … & UK IBD Genetics Consortium. (2020). Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort. Gastroenterology.
Find more updates from the Cho Lab here.
About the Cho Lab
The Cho Laboratory investigates the genetic and immunologic factors associated with Crohn’s Disease and Ulcerative Colitis, collectively known as Inflammatory Bowel Diseases (IBD). We are part of the Department of Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai, NY.
A major focus of our research is understanding the prevalence of IBD in the Ashkenazi Jewish population. We are working on further identifying rare disease associated variants in Ashkenazi Jewish population by Exome Chip technology as well as the biological function of those identified genes. Dr. Cho’s research has contributed to defining the pathophysiologic mechanisms of IBD by identifying associations to NOD2, IL23R, and 163 loci to IBD. With new findings our research is evolving to now looking at the function of lipid mediators and their related cytokines in innate immune cells, and the full transcriptome of enteroids, the intestinal epithelial stem cells.
Follow us @MountsinaiIBD ║ Charles Bronfman Institute for Personalized Medicine